Previous close | 2.6500 |
Open | 2.1300 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 2.1300 - 2.1300 |
52-week range | 2.1300 - 3.3700 |
Volume | |
Avg. volume | 27 |
Market cap | 189.746M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial […]
Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.